Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:01:11 EDT Fri 04 Sep 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:HCM - HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
HCM - Q2.813.21·14.502.014.09-0.02-0.1150.52,0061,11214.25  14.325  14.06518.29  9.7716:43:09Sep 0315 min RT 2¢

Recent Trades - Last 10 of 1112
Time ETExPriceChangeVolume
16:43:09Q14.00-0.11500
16:43:09Q14.00-0.11227
16:10:04Q14.09-0.021
16:10:04Q14.09-0.021
16:10:04Q14.09-0.021
16:10:04Q14.09-0.021
16:04:03Q14.09-0.021
16:04:03Q14.09-0.021
16:04:02Q14.09-0.021
16:04:02Q14.09-0.021

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-09-03 00:00U:HCMNews ReleaseHUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
2026-08-30 20:00U:HCMNews ReleaseHUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS(TM) Plus TAGRISSO(TM) in Treatment-Naive Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
2026-08-27 20:00U:HCMNews ReleaseHUTCHMED Announces NMPA Approval for ATLED(TM) (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
2026-08-16 20:00U:HCMNews ReleaseHUTCHMED Announces ORPATHYS(TM) Plus TAGRISSO(TM) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO(TM)
2026-07-30 07:00U:HCMNews ReleaseHUTCHMED Reports 2026 Interim Results
2026-07-02 04:30U:HCMNews ReleaseHUTCHMED Announces NMPA Approval for ORPATHYS(TM) for the treatment of Gastric Cancer Patients with MET Amplification
2026-06-30 04:30U:HCMNews ReleaseHUTCHMED to Announce 2026 Half-Year Financial Results
2026-06-24 20:00U:HCMNews ReleaseHUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
2026-06-11 20:00U:HCMNews ReleaseHUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
2026-05-21 20:00U:HCMNews ReleaseHUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
2026-05-21 06:00U:HCMNews ReleaseHUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE(TM) (Fruquintinib) in Combination with TYVYT(TM) (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
2026-04-29 06:00U:HCMNews ReleaseHUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
2026-04-08 20:00U:HCMNews ReleaseHUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
2026-03-22 20:00U:HCMNews ReleaseHUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
2026-03-09 05:30U:HCMNews ReleaseHUTCHMED Announces Update on Licensed Oncology Product TAZVERIK(TM) in China
2026-03-06 03:30U:HCMNews ReleaseIntended Retirement of Independent Non-executive Director and changes of composition of board committees
2026-03-05 06:00U:HCMNews ReleaseHUTCHMED Reports 2025 Full Year Results and Business Updates
2026-03-04 03:30U:HCMNews ReleaseHUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
2026-02-06 03:30U:HCMNews ReleaseHUTCHMED to Announce 2025 Final Results
2026-01-13 23:00U:HCMNews ReleaseHUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet